BioSource agrees Japanese purchases:
This article was originally published in Clinica
Executive Summary
US diagnostics company BioSource International has signed a minimum purchase agreement with its Japanese distributor for 1997. Under the deal, Iwaki Glass will purchase no less than $2 million-worth of BioSource products for sale in Japan. BioSource, which is based in Camarillo, California, has also begun private-label manufacturing with Japanese companies. As a result of the two developments, BioSource expects its Japanese revenues to increase from around $1.4 million in 1996 to $3.25 million in 1997.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.